

Anna Tosi

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4736675/publications.pdf>

Version: 2024-02-01

14
papers

153
citations

1307594

7
h-index

1199594

12
g-index

14
all docs

14
docs citations

14
times ranked

165
citing authors

#	ARTICLE	IF	CITATIONS
1	Neoadjuvant Chemotherapy and Immunotherapy in Luminal B-like Breast Cancer: Results of the Phase II GIADA Trial. <i>Clinical Cancer Research</i> , 2022, 28, 308-317.	7.0	36
2	A comprehensive profiling of the immune microenvironment of breast cancer brain metastases. <i>Neuro-Oncology</i> , 2022, 24, 2146-2158.	1.2	9
3	Hyaluronan is a natural and effective immunological adjuvant for protein-based vaccines. <i>Cellular and Molecular Immunology</i> , 2021, 18, 1197-1210.	10.5	14
4	The immune cell landscape of metastatic uveal melanoma correlates with overall survival. <i>Journal of Experimental and Clinical Cancer Research</i> , 2021, 40, 154.	8.6	19
5	Profiling of immune checkpoint biomarkers by multiplex immunofluorescence in breast cancer brain metastases. <i>Journal of Clinical Oncology</i> , 2021, 39, 2021-2021.	1.6	5
6	129P Integration of gene expression and tumor-infiltrating lymphocytes (TILs) to predict pCR after neoadjuvant chemotherapy and nivolumab for patients with luminal B-like breast cancer in the phase II GIADA trial. <i>Annals of Oncology</i> , 2021, 32, S414.	1.2	1
7	281P Prognostic impact of immune interactions in HER2+ and triple-negative breast cancer brain metastases. <i>Annals of Oncology</i> , 2021, 32, S486-S487.	1.2	0
8	Reduced Interleukin-17-Expressing Cells in Cutaneous Melanoma. <i>Biomedicines</i> , 2021, 9, 1930.	3.2	2
9	Reduction of T Lymphoma Cells and Immunological Invigoration in a Patient Concurrently Affected by Melanoma and Sezary Syndrome Treated With Nivolumab. <i>Frontiers in Immunology</i> , 2020, 11, 579894.	4.8	4
10	162MO Neoadjuvant chemotherapy and immunotherapy in Luminal B BC: Results of the phase II GIADA trial. <i>Annals of Oncology</i> , 2020, 31, S304-S305.	1.2	7
11	Adoptive cell therapy of triple negative breast cancer with redirected cytokine-induced killer cells. <i>Oncolimmunology</i> , 2020, 9, 1777046.	4.6	24
12	Immune microenvironment profiling of breast cancer brain metastases using multiplex immunofluorescence. <i>Journal of Clinical Oncology</i> , 2020, 38, 2526-2526.	1.6	0
13	Identification of a HLA-A*0201-restricted immunogenic epitope from the universal tumor antigen DEPDC1. <i>Oncolimmunology</i> , 2017, 6, e1313371.	4.6	11
14	Retargeting cytokine-induced killer cell activity by CD16 engagement with clinical-grade antibodies. <i>Oncolimmunology</i> , 2016, 5, e1199311.	4.6	21